Geisinger announcements of innovations and new mergers usually are big news. The health system topped off 2018 with the announcement in November that President and Chief Executive Officer Dr. David Feinberg was leaving the health system at the end of the year to head Google's new health initiative.
The same emailed news release also stated the Geisinger board of directors appointed Dr. Jaewon Ryu interim president and CEO, effective Dec. 1. Ryu has been executive vice president and chief medical officer since September 2016.
Feinberg is leaving Jan. 3 for his new job.
“It has been a great privilege to lead Geisinger during the past nearly four years," Feinberg said in a prepared statement. "Together, we have improved patient and member experience, along with our quality of care, employee engagement and physician and nurse recruitment, and our legacy of innovation has blossomed.”
Feinberg, 56, arrived in Danville in May 2015 to lead the sprawling health care system. He came to Geisinger from UCLA Health System, where he had served as CEO of UCLA’s hospitals and associate vice chancellor of UCLA Health Sciences, as well as president of UCLA Health System.
Since coming to Geisinger, Feinberg grew to prominence on the national health care stage, overseeing new initiatives such as Geisinger’s ProvenExperience, to provide refunds to patients unhappy with their care experience, and Geisinger’s MyCode, what Geisinger says is the largest health care system-based precision health project in the world. It includes a system-wide biobank designed to store blood and other samples for research use by Geisinger and Geisinger collaborators to try to diagnose medical conditions earlier.
In July, the health system started its new DNA screening program. Feinberg was the first to have blood drawn to kickstart the program, the first of its kind in the nation.